BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16736417)

  • 1. Chronic and acute consequences of a post-dialysis urokinase lock on permanent hemodialysis catheter function.
    Gabutti L; Mosconi E; Pellegrini L; Duchini F; Marone C
    J Nephrol; 2006; 19(2):183-8. PubMed ID: 16736417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of catheter-restricted filling with cefotaxime and heparin on the lifespan of temporary hemodialysis catheters: a case controlled study.
    Saxena AK; Panhotra BR
    J Nephrol; 2005; 18(6):755-63. PubMed ID: 16358235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase efficacy in the restoration of hemodialysis catheter function.
    Meers C; Toffelmire EB
    J CANNT; 1998; 8(2):17-9. PubMed ID: 9807329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tesio twin catheter system for hemodialysis tunnelized using an echo-guided technique. Retrospective analysis of 210 catheters].
    Ibrik O; Samon R; Roca R; Viladoms J; Mora J
    Nefrologia; 2006; 26(6):719-25. PubMed ID: 17227250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of urokinase lock to treat thrombotic dysfunction of tunneled hemodialysis catheters: A retrospective cohort study.
    Van Hulle F; Bonkain F; De Clerck D; Aerden D; Vanwijn I; Tielemans C; Wissing KM
    J Vasc Access; 2019 Jan; 20(1):60-69. PubMed ID: 29893163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catheter lock heparin concentration: effects on tissue plasminogen activator use in tunneled cuffed catheters.
    Holley JL; Bailey S
    Hemodial Int; 2007 Jan; 11(1):96-8. PubMed ID: 17257362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative study between 20 IU/ml heparin and 5% heparin/urokinase 5000 IU lock in hemodialysis central venous catheters with permeability problems].
    Pelayo Alonso R; Cobo Sánchez JL; de Buruaga Perea AS; Menezo Viadero R; Gándara Revuelta M; Aja Crespo A; Tovar Rincón A
    Rev Enferm; 2013 Mar; 36(3):8-12. PubMed ID: 23654184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombosis of tunneled-cuffed hemodialysis catheters: treatment with high-dose urokinase lock therapy.
    Donati G; Colì L; Cianciolo G; La Manna G; Cuna V; Montanari M; Gozzetti F; Stefoni S
    Artif Organs; 2012 Jan; 36(1):21-8. PubMed ID: 21848863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study.
    Al-Ali F; Hamdy AF; Hamad A; Elsayed M; Zafar Iqbal Z; Elsayed A; Ibrahim R; Tolba H; Buanan H; Fawzy A
    Nephrol Dial Transplant; 2018 Apr; 33(4):619-626. PubMed ID: 29106676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
    Winnicki W; Herkner H; Lorenz M; Handisurya A; Kikić Ž; Bielesz B; Schairer B; Reiter T; Eskandary F; Sunder-Plassmann G; Sengoelge G
    Kidney Int; 2018 Mar; 93(3):753-760. PubMed ID: 28890326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose intradialytic urokinase to restore the patency of permanent central vein hemodialysis catheters.
    Twardowski ZJ
    Am J Kidney Dis; 1998 May; 31(5):841-7. PubMed ID: 9590195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue plasminogen activator as a hemodialysis catheter locking solution.
    McGill RL; Spero JA; Sysak JC; Sandroni SE; Marcus RJ
    Hemodial Int; 2008 Jul; 12(3):348-51. PubMed ID: 18638092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial.
    Power A; Duncan N; Singh SK; Brown W; Dalby E; Edwards C; Lynch K; Prout V; Cairns T; Griffith M; McLean A; Palmer A; Taube D
    Am J Kidney Dis; 2009 Jun; 53(6):1034-41. PubMed ID: 19394731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do central venous catheters have advantages over arteriovenous fistulas or grafts?
    Quarello F; Forneris G; Borca M; Pozzato M
    J Nephrol; 2006; 19(3):265-79. PubMed ID: 16874685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Catheter lock solution--taurolock for prevention of catheter-related bacteremia in hemodialysis patients].
    Geron R; Tanchilevski O; Kristal B
    Harefuah; 2006 Dec; 145(12):881-4, 943. PubMed ID: 17220025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful prevention of cuffed hemodialysis catheter-related infection using an antibiotic lock technique by strictly catheter-restricted antibiotic lock solution method.
    Zhang P; Yuan J; Tan H; Lv R; Chen J
    Blood Purif; 2009; 27(2):206-11. PubMed ID: 19176949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the heparin lock concentration affect hemodialysis catheter patency?
    Ivan DM; Smith T; Allon M
    Clin J Am Soc Nephrol; 2010 Aug; 5(8):1458-62. PubMed ID: 20498241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing the survival of tunneled haemodialysis catheters using an antibiotic lock in the elderly: a randomised, double-blind clinical trial.
    Saxena AK; Panhotra BR; Sundaram DS; Morsy MN; Al-Ghamdi AM
    Nephrology (Carlton); 2006 Aug; 11(4):299-305. PubMed ID: 16889569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase-containing locking solution in the prevention of dialysis catheter dysfunction: a double blind randomized controlled trial.
    Bonkain F; Van Hulle F; Janssens P; Catalano C; Allamani M; Stolear JC; Vandervelde D; Libertalis M; Treille S; Couttenye MM; Dhondt A; Van Biesen W; Fils JF; Tielemans C; Wissing KM
    J Vasc Access; 2017 Sep; 18(5):436-442. PubMed ID: 28623638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of tunneled cuffed catheter dysfunction with prophylactic use of a taurolidine urokinase lock: A randomized double-blind trial.
    Bonkain F; Stolear JC; Catalano C; Vandervelde D; Treille S; Couttenye MM; Dhondt A; Libertalis M; Allamani M; Madhoun P; Van Craenenbroeck AH; Vanommeslaeghe F; Van Hulle F; Durieux P; Van Limberghen I; Tielemans C; Wissing KM
    PLoS One; 2021; 16(5):e0251793. PubMed ID: 34015014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.